Clinical Trials Browser

NCT07396454 2026-02-09

Study on the Treatment of HER2-negative Breast Cancer Brain Metastases With Radiotherapy Combined With Anlotinib

Phase 2 Recruiting

39 enrolled

Breast

HER2-Negative Breast Cancer

NCT07139470 2025-08-24

Sacituzumab Tirumotecan Plus Anlotinib for Metastatic Triple Negative Breast Cancer

Phase 1/2 Not yet recruiting

59 enrolled

Breast

Triple Negative Breast Neoplasms

NCT06874933 2025-08-12

Neoadjuvant Chemotherapy in Combination With Anlotinib and Benmelstobart for HR+/HER2- Breast Cancer (NEOTORCH-BREAST03)

Phase 2 Recruiting

35 enrolled

Breast

Breast Neoplasms

NCT06992336 2025-05-28

Circulating Tumor DNA Guided Boost Therapy in Early Triple Negative Breast Patients With Residual Disease After Neoadjuvant Therapy

Phase 2 Recruiting

411 enrolled

Breast

Breast Neoplasms

NCT06678230 2024-11-07

Clinical Trial of Eribulin in Combination with Anrotinib for HER-2 Negative Locally Advanced or Metastatic Breast Cancer

Phase 2 Unknown

40 enrolled

Breast

Breast Neoplasms

NCT06605690 2024-09-20

An Exploratory Clinical Study of Dalpiciclib an&Amp;#39;d Letrozole Combined With Anlotinib Neoadjuvant Therapy in Stage II-III Postmenopausal HR+/HER2- Early Breast Cancer

Phase NA Not yet recruiting

30 enrolled

Breast

Breast Neoplasms

NCT06331169 2024-08-30

Anlotinib With Trastuzumab Deruxtecan for Previously Treated HER2-Low Advanced Breast Cancer

Phase 1 Recruiting

42 enrolled

Breast

Breast Neoplasms

NCT06340165 2024-04-01

A Real-world Efficacy and Safety Study of Amlotinib for HER2-negative Advanced Breast Cancer

Unknown

153 enrolled

Breast

Breast Neoplasms

NCT04914390 2024-01-22

NeoATCT

Phase 2 Unknown

32 enrolled

Breast

Triple Negative Breast Neoplasms

NCT06015126 2023-08-29

Efficacy and Safety of Metronomic Oral Vinorelbine Plus Anlotinib in HER2-negative Metastatic Breast Cancer Patients

Phase NA Unknown

60 enrolled

Breast

Breast Neoplasms

NCT05206656 2022-11-23

Safety and Efficacy of Eribullin or Eribulin Combined With Anlotinib in Metastatic Breast Cancer

Phase 2 Completed

80 enrolled

Breast

Breast Neoplasms

NCT05558722 2022-09-28

ACNTBC

Phase 2 Unknown

30 enrolled

Breast

Breast Neoplasms

NCT05089643 2022-01-10

Anrotinib in Combination With Capecitabine in Advanced Triple Negative Breast Cancer

Phase 2 Unknown

35 enrolled

Breast

Triple Negative Breast Neoplasms

NCT05075512 2021-10-12

The Efficacy and Safety of Anlotinib Combined With Fulvestrant in Patients With Advanced Breast Cancer

Phase 2 Recruiting

40 enrolled

Breast

Breast Neoplasm Female

NCT04975451 2021-07-27

ADCb (Anlotinib/Docetaxel/Carboplatin) as Neoadjuvant Therapy for Triple-Negative Breast Cancer

Phase 2 Unknown

30 enrolled

Breast

Breast Neoplasms

NCT04452370 2021-07-21

Oral Etoposide Combined With Anlotinib in Advanced Triple Negative Breast Cancer

Phase 2 Unknown

100 enrolled

Breast

Triple Negative Breast Neoplasms

NCT04936295 2021-06-23

Fulvestrant Plus Anlotinib in HR(+)/HER2(-) Metastatic Breast Cancer With FGFR Mutation

Phase 2 Unknown

61 enrolled

Breast

Breast Neoplasms

NCT04764084 2021-02-21

Niraparib Combined With Anlotinib in Homologous Recombination Repair (HRR) Gene-mutated Advanced Solid Tumors

Phase 1 Unknown

52 enrolled

BreastGastrointestinal

Breast Neoplasms, Pancreatic Neoplasms, Cholangiocarcinoma

NCT04002284 2020-07-29

Anlotinib in Metastatic HER2 Negative Breast Cancer

Phase 2 Completed

26 enrolled

Breast

Breast Neoplasms

NCT04405505 2020-05-28

A Study of TQB2450 Injection Combined With Anlotinib Hydrochloride Capsule Versus Paclitaxel for Injection (Albumin Bound) in Subjects With Triple Negative Breast Cancer (TNBC)

Phase 3 Unknown

332 enrolled

Breast

Triple Negative Breast Neoplasms